Table of Contents
1. Preface
2. Assumptions and Research Methodology
3. Executive Summary: Global Market
4. Market Overview
5. Market Outlook
6. Global Market Analysis and Forecast, by Route of Administration
- 6.1. Oral
- 6.2. Injectable
7. Global Market Analysis and Forecast, by Drug Class
- 7.1. Factor XA Inhibitors (NOAC/DOAC)
- 7.2. Heparins
- 7.3. Direct Thrombin Inhibitors
- 7.4. Vitamin K Antagonists
8. Global Market Analysis and Forecast, by Indication
- 8.1. Deep Vein Thrombosis
- 8.2. Pulmonary Embolism
- 8.3. Atrial Fibrillation & Heart Attack
- 8.4. Others
9. Global Market Analysis and Forecast, by Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Online Pharmacies
10. Global Market Analysis and Forecast, by Region
- 10.1. North America
- 10.2. Europe
- 10.3. Asia Pacific
- 10.4. Latin America
- 10.5. Middle East & Africa
11. North America Market Analysis and Forecast
12. Europe Market Analysis and Forecast
13. Asia Pacific Market Analysis and Forecast
14. Latin America Market Analysis and Forecast
15. Middle East & Africa Market Analysis and Forecast
16. Competition Landscape
- 16.1. Bayer AG
- 16.2. Boehringer Ingelheim International GmbH
- 16.3. Bristol-Myers Squibb Company
- 16.4. Daiichi Sankyo Company, Limited
- 16.5. Sanofi
- 16.6. Johnson & Johnson Services
List of Tables
Table 01: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 02: Global Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 03: Global Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 04: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 05: Global Market Size (US$ Mn) and Volume (Units) Forecast, by Region, 2021 to 2031
Table 06: North America Market Value (US$ Mn) Forecast, by Country, 2016 to 2031
Table 07: North America Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 08: North America Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 09: North America Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 10: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 11: Europe Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 12: Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 13: Europe Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 14: Europe Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 15: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 16: Asia Pacific Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 17: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 18: Asia Pacific Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 19: Asia Pacific Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 20: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 21: Latin America Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 22: Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 23: Latin America Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 24: Latin America Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 25: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 26: Middle East & Africa Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 27: Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 28: Middle East & Africa Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 29: Middle East & Africa Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 30: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
List of Figures
Figure 01: Global Market Size Value (US$ Mn) Forecast, 2016 to 2031
Figure 02: Global Market Value Share (%), by Route of Administration, 2021
Figure 03: Global Market Value Share (%), by Drug Class, 2021
Figure 04: Global Market Value Share (%), by End-user, 2021
Figure 05: Global Market Value Share (%), by Region, 2021
Figure 06: Global Market Value Share, by Route of Administration, 2021 and 2031
Figure 07: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2016 to 2031
Figure 08: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Injectables, 2016 to 2031
Figure 09: Global Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 10: Global Market Value Share, by Drug Class, 2021 and 2031
Figure 11: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Factor XA Inhibitors, 2016 to 2031
Figure 12: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Heparins, 2016 to 2031
Figure 13: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Direct Thrombin Inhibitors, 2016 to 2031
Figure 14: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Vitamin K Antagonists, 2016 to 2031
Figure 15: Global Market Attractiveness, by Drug Class, 2021 to 2031
Figure 16: Global Market Value Share, by Indication, 2021 and 2031
Figure 17: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Deep Vein Thrombosis (DVT), 2016 to 2031
Figure 18: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pulmonary Embolism (PE), 2016 to 2031
Figure 19: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Atrial Fibrillation & Heart Attack, 2016 to 2031
Figure 20: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016 to 2031
Figure 21: Global Market Attractiveness, by Indication, 2021 to 2031
Figure 22: Global Market Value Share, by Distribution Channel, 2021 and 2031
Figure 23: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals Pharmacies, 2016 to 2031
Figure 24: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2016 to 2031
Figure 25: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016 to 2031
Figure 26: Global Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 27: Global Market Value Share Analysis, by Region, 2021 and 2031
Figure 28: Global Market Attractiveness Analysis, by Region, 2021 and 2031
Figure 29: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 30: North America Market Value Share, by Country, 2021 and 2031
Figure 31: North America Market Attractiveness, by Country, 2021 to 2031
Figure 32: North America Market Value Share, by Route of Administration, 2021 and 2031
Figure 33: North America Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 34: North America Market Value Share, by Drug Class, 2021 and 2031
Figure 35: North America Market Attractiveness, by Drug Class, 2021 to 2031
Figure 36: North America Market Value Share, by Indication, 2021 and 2031
Figure 37: North America Market Attractiveness, by Indication, 2021 to 2031
Figure 38: North America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 39: North America Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 40: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 41: Europe Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 42: Europe Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 43: Europe Market Value Share, by Route of Administration, 2021 and 2031
Figure 44: Europe Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 45: Europe Market Value Share, by Drug Class, 2021 and 2031
Figure 46: Europe Market Attractiveness, by Drug Class, 2021 to 2031
Figure 47: Europe Market Value Share, by Indication, 2021 and 2031
Figure 48: Europe Market Attractiveness, by Indication, 2021 to 2031
Figure 49: Europe Market Value Share, by Distribution Channel, 2021 and 2031
Figure 50: Europe Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 51: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 52: Asia Pacific Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 53: Asia Pacific Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 54: Asia Pacific Market Value Share, by Route of Administration, 2021 and 2031
Figure 55: Asia Pacific Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 56: Asia Pacific Market Value Share, by Drug Class, 2021 and 2031
Figure 57: Asia Pacific Market Attractiveness, by Drug Class, 2021 to 2031
Figure 58: Asia Pacific Market Value Share, by Indication, 2021 and 2031
Figure 59: Asia Pacific Market Attractiveness, by Indication, 2021 to 2031
Figure 60: Asia Pacific Market Value Share, by Distribution Channel, 2021 and 2031
Figure 61: Asia Pacific Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 62: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 63: Latin America Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 64: Latin America Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 65: Latin America Market Value Share, by Route of Administration, 2021 and 2031
Figure 66: Latin America Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 67: Latin America Market Value Share, by Drug Class, 2021 and 2031
Figure 68: Latin America Market Attractiveness, by Drug Class, 2021 to 2031
Figure 69: Latin America Market Value Share, by Indication, 2021 and 2031
Figure 70: Latin America Market Attractiveness, by Indication, 2021 to 2031
Figure 71: Latin America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 72: Latin America Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 73: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 74: Middle East & Africa Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 75: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 76: Middle East & Africa Market Value Share, by Route of Administration, 2021 and 2031
Figure 77: Middle East & Africa Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 78: Middle East & Africa Market Value Share, by Drug Class, 2021 and 2031
Figure 79: Middle East & Africa Market Attractiveness, by Drug Class, 2021 to 2031
Figure 80: Middle East & Africa Market Value Share, by Indication, 2021 and 2031
Figure 81: Middle East & Africa Market Attractiveness, by Indication, 2021 to 2031
Figure 82: Middle East & Africa Market Value Share, by Distribution Channel, 2021 and 2031
Figure 83: Middle East & Africa Market Attractiveness, by Distribution Channel, 2021 to 2031
Who worked on this report
Preview the report firsthand - request a free sample
Free SampleGet the brochure for pricing and purchase details
Download PDF